| Autor: |
Bhojani MS; Department of Radiation Oncology, University of Michigan Cancer Center, University of Michigan, Ann Arbor, MI, USA., Nyati MK, Zhao L, Normolle DP, Ross BD, Lawrence TS, Rehemtulla A |
| Jazyk: |
angličtina |
| Zdroj: |
Translational oncology [Transl Oncol] 2011 Jun; Vol. 4 (3), pp. 122-5. Date of Electronic Publication: 2011 Jun 01. |
| DOI: |
10.1593/tlo.11112 |
| Abstrakt: |
Development of noninvasive, real-time molecular imaging tools to assess responsiveness of a given therapy may be a critical component of the success of individualized therapy approach for patients. Toward this, we have previously developed and validated molecular sensors for Akt and caspase-3 activity, and in this report, we have explored the utility of these reporters in assessing the responsiveness of tumors to a combination of gemcitabine (Gem) and cetuximab (Cet) delivered in two opposite schedules. We found that human head and neck cancer (UMSCC1) xenografts responded significantly better in a schedule where cetuximab was administered after gemcitabine when compared with the schedule of cetuximab followed by gemcitabine. Wilcoxon two-sample tests suggested that the difference in tumor volumes in two schedules became significant on day 7 (P > .05 on day 4, and P < .05 on days 7 and 10), and the difference in activity of Akt in two schedules became significant on day 4 (P < .05 on days 4, 6, and 10). Using Akt reporter activity and cubic spline interpolation, the distinction between the two schedules could be detected 2 days before using the tumor volume, suggesting that molecular imaging of Akt may allow early prediction of therapy responsiveness. We did not observe a significant difference between the two schedules in the caspase-3 activity. In summary, this proof-of-concept study provides a basis for using molecular imaging of Akt as an early indicator of therapeutic efficacy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
